Targeting the epidermal growth factor receptor (EGFR)--a new therapeutic option in oncology?

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) is frequently overexpressed in solid tumors, playing a crucial role in cancer development and progression.
• EGFR's involvement in cancer makes it a significant target for therapeutic interventions.

Purpose of the Study:

• To review the main classes of anti-EGFR therapeutics: monoclonal antibodies and tyrosine-kinase inhibitors.
• To discuss the clinical efficacy and future prospects of EGFR-targeted cancer therapies.

Main Methods:

• Review of clinical trial data for monoclonal antibodies and tyrosine-kinase inhibitors targeting EGFR.
• Analysis of biological factors associated with treatment response to EGFR inhibitors.

Main Results:

• Monoclonal antibodies targeting the extracellular domain and small molecules inhibiting intracellular tyrosine-kinase activation have shown clinical activity.
• EGFR gene amplification, high polysomy, high protein expression, and mutations are linked to better responses to tyrosine-kinase inhibitors.

Conclusions:

• EGFR-targeted therapies, particularly monoclonal antibodies and tyrosine-kinase inhibitors, represent important strategies in cancer treatment.
• Future research should focus on identifying predictive biomarkers, combination therapies, and earlier application of EGFR inhibitors in cancer treatment.